ARTICLE
22 January 2021

COVID-19 Key EU Developments, Policy & Regulatory Update No. 31

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.
European Union Coronavirus (COVID-19)

This regular alert covers key regulatory EU developments related to the COVID-19 situation. It does not purport to provide an exhaustive overview of developments and contains no analysis or opinion.

LATEST KEY DEVELOPMENTS

Competition & State Aid

  • ?25 billion Pan-European Guarantee Fund deployed for the first time
  • EU approves new and amended Member State measures to support the economy

Trade / Export Controls

  • No noteworthy items for this issue

Medicines, Medical Devices, and Personal Protective Equipment

  • European Medicines Agency starts evaluation of AstraZeneca COVID-19 vaccine
  • Commission concludes exploratory talks with Valneva to secure an additional COVID-19 vaccine
  • Commission issues Notice in relation to medical devices, including temporary measures for remote audits for assessing quality management systems
  • European Commission grants conditional marketing authorization for Moderna COVID-19 vaccine

Cybersecurity, Privacy & Data Protection

  • European Medicines Agency pursues investigation of cyberattack

To view the full article, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More